INSULIN REZISTENTLIK VA METABOLIK SINDROM: ZAMONAVIY PATOGENETIK VA KLINIK QARAShLAR
PDF

Keywords

insulin rezistentlik, metabolik sindrom, abdominal semirish, giperinsulinemiya, dislipidemiya, arterial gipertenziya, yurak-qon tomir kasalliklari.

Abstract

Insulin rezistentlik va metabolik sindrom zamonaviy tibbiyotda eng dolzarb muammolardan biri bo‘lib, ular yurak-qon tomir kasalliklari va 2-tip qandli diabet rivojlanishida asosiy patogenetik omil sifatida qaraladi [1,2]. Insulin rezistentlik — to‘qimalarning insulin gormoniga biologik javobining pasayishi bilan tavsiflanadigan holat bo‘lib, uglevod, lipid va oqsil almashinuvi buzilishlari bilan kechadi [3]. Metabolik sindrom esa abdominal semirish, arterial gipertenziya, dislipidemiya va glyukoza almashinuvi buzilishlarini o‘z ichiga olgan kompleks sindrom hisoblanadi [4]. Ushbu obzor maqolada insulin rezistentlik va metabolik sindromning etiologiyasi, patogenezi, klinik ahamiyati, shuningdek zamonaviy diagnostik va davolash yondashuvlari ilmiy adabiyotlar asosida tahlil qilingan.

PDF

References

1. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2020;30(4):238–244.

2. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2020;26(5):678–689.

3. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20:12.

4. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2024;47(Suppl 1):S19–S40.

5. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome. BMC Med. 2021;19:48.

6. Smith U, Kahn BB. Adipose tissue and insulin sensitivity. J Intern Med. 2021;289:644–659.

7. International Diabetes Federation. IDF consensus on metabolic syndrome. Brussels; 2022.

8. Blüher M. Metabolically healthy obesity. Endocr Rev. 2020;41:405–420.

9. Magkos F, Hjorth MF, Astrup A. Diet and exercise in T2DM prevention. Nat Rev Endocrinol. 2022;18:363–376.

10. Rochlani Y, Pothineni NV, Mehta JL. Metabolic syndrome and CV risk. Cardiovasc Drugs Ther. 2021;35:53–64.

11. Ridker PM. Inflammation and atherosclerosis. Circulation. 2012;105:1135–1143.

12. Lau DCW, et al. Adipokines. Nat Rev Endocrinol. 2017;13:447–459.

13. Bluher M. Obesity and insulin resistance. Endocr Rev. 2020;41:405–420.

14. Choy E. Inflammation and insulin resistance. Rheumatology. 2012;51:393–400.